FOR IMMEDIATE RELEASE: September 14, 2023 Results of the second, confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder, MAPP2, have been published in Nature Medicine. MAPP2 …
It was at an IACP conference in Florida, the largest event for police officers in the world, that Gergerian met Rick Doblin, the former hippie and founder of Maps (an acronym in English for “Multidisciplinary …
MDMA has been gaining attention for its potential therapeutic applications. In recent years, MDMA therapy, particularly MDMA-assisted psychotherapy, has been a topic of extensive research, with MAPS’ …
The code was the result of a partnership between U.K.-based COMPASS Pathways and the Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation to facilitate access and insurance …
Quote Originally appearing here (Archived)
FOR IMMEDIATE RELEASE: April 5, 2023 MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), announced preliminary findings …
The bill – HD 2137, by state Rep. Nicholas Boldyga – was introduced in January, apparently in response to reporting by The Washington Post and The New York Times regarding moves by the nonprofit …
The world's most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
Since the final participant for this MAPP2 was treated on November 17, 2022, the database has been locked and is being analyzed. This study is our second Phase 3 trial of MDMA-assisted therapy for posttraumatic …
MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase 3 Study of MDMA-Assisted Therapy for …
Enrollment continues in MPLONG, a long-term follow-up observational study for participants in MAPS-sponsored Phase 3 studies of MDMA-assisted therapy for the treatment of PTSD. You are eligible to participate …
Our Bronx VA study site continues to actively screen for new participants. Enrollment is continuing for this Phase 2, open-label study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with …
